Fig. 6

Plaque load remains unchanged by TWF9 treatment. Soluble levels of Aβ42/40 in the brain trend toward change in TWF9-treated female mice. a Representative images of amyloid plaque burden in subiculum of old 3xTg-AD and nontransgenic (NTg) mice. Scale bar = 100 μm. b Analysis of amyloid plaque burden measured as percentage of subiculum area covered by amyloid plaques. Quantification of amyloid plaques in subiculum stained with 4G8/6E10 from two to four sections per mouse (****p < 0.0001 by Kruskal-Wallis test followed by the Dunn’s multiple comparisons test); n = 11 for transgenic (Tg) treated (Tx), n = 12 for Tg saline, n = 11 for NTg Tx, n = 9 for NTg saline. Data shown as mean ± SD. NTg Tx vs Tg Tx (**p < 0.01), NTg Tx vs Tg saline (*p < 0.05), NTg saline vs Tg Tx (**p < 0.01), and NTg saline vs Tg saline (*p < 0.05). c The ratio of Aβ42/Aβ40 was measured in the S1 fraction of brain homogenates in female 3xTg-AD and NTg mice. Quantification of the ratio of Aβ42/Aβ40 by ELISA (**p < 0.01 by one-way ANOVA followed by Tukey’s multiple comparisons test). Results shown for females (n = 5 for Tg Tx, n = 6 for Tg saline, n = 5 for NTg Tx, n = 5 for NTg saline) as mean ± SD. Quantification of soluble levels of Aβ42/Aβ40 for Tg saline vs Tg Tx (^#p = 0.0554), Tg saline vs NTg Tx (**p < 0.01), and Tg saline vs NTg saline (**p < 0.01)